IGC Pharma Inc IGC Stock Analysis
- NYSE American
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.20 up $0.01, 5.82% at close Nov 6
Last close · Previous close $0.19
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.07Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.20down $0.08, 28.57%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.19Nov 5
- Volume615.17KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume528.23KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.08 to $0.40; now $0.20
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
IGC trailed the S&P 500 in all 7 periods.
| Period | IGC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IGC: down 28.6% S&P 500: down 5.6% | IGC trailed the S&P 500 by 23.0 percentage points Trailed |
| 3M | IGC: down 20.0% S&P 500: down 4.1% | IGC trailed the S&P 500 by 15.9 percentage points Trailed |
| YTD | IGC: down 28.9% S&P 500: up 8.7% | IGC trailed the S&P 500 by 37.6 percentage points Trailed |
| 1Y | IGC: down 48.1% S&P 500: up 10.9% | IGC trailed the S&P 500 by 59.0 percentage points Trailed |
| Long term | ||
| 3Y | IGC: down 33.8% S&P 500: up 75.0% −12.8% vs +20.5% a year | IGC trailed the S&P 500 by 108.8 percentage points Trailed |
| 5Y | IGC: down 85.8% S&P 500: up 67.8% −32.3% vs +10.9% a year | IGC trailed the S&P 500 by 153.6 percentage points Trailed |
| 10Y | IGC: down 48.4% S&P 500: up 313.1% −6.4% vs +15.2% a year | IGC trailed the S&P 500 by 361.5 percentage points Trailed |
$10,000 invested in IGC 10 years ago (Nov 4, 2016) would be worth about $5,163 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
IGC trailed the S&P 500 in all 7 periods.
| Period | IGC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IGC: down 28.6% S&P 500: down 5.6% | IGC trailed the S&P 500 by 23.0 percentage points Trailed |
| 3M | IGC: down 20.0% S&P 500: down 4.3% | IGC trailed the S&P 500 by 15.7 percentage points Trailed |
| YTD | IGC: down 28.9% S&P 500: up 7.8% | IGC trailed the S&P 500 by 36.7 percentage points Trailed |
| 1Y | IGC: down 48.1% S&P 500: up 9.7% | IGC trailed the S&P 500 by 57.8 percentage points Trailed |
| Long term | ||
| 3Y | IGC: down 33.8% S&P 500: up 68.8% −12.8% vs +19.1% a year | IGC trailed the S&P 500 by 102.6 percentage points Trailed |
| 5Y | IGC: down 85.8% S&P 500: up 56.9% −32.3% vs +9.4% a year | IGC trailed the S&P 500 by 142.7 percentage points Trailed |
| 10Y | IGC: down 48.4% S&P 500: up 252.6% −6.4% vs +13.4% a year | IGC trailed the S&P 500 by 301.0 percentage points Trailed |
$10,000 invested in IGC 10 years ago (Nov 4, 2016) would be worth about $5,163 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$59.40
Closing high on . Now 99.7% below that record.
Split-adjusted daily closes since Apr 13, 2006.
Stock splits
1
1-for-10 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY26, the quarter ended Mar 31, 2026. “Last 12 months” means the four quarters from Apr 1, 2025 to Mar 31, 2026, and balance-sheet figures are as of Mar 31, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.19Mdown 6.7%
- Net income
- −$6.55M
- Diluted EPS
- −$0.07
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q1 FY25 (Jun 30, 2024) | $272.00K | −$2.38M | −$0.03 |
| Q2 FY25 (Sep 30, 2024) | $412.00K | −$1.72M | −$0.02 |
| Q3 FY25 (Dec 31, 2024) | $257.00K | −$1.83M | −$0.02 |
| Q4 FY25 (Mar 31, 2025) | $330.00K | −$1.20M | −$0.02 |
| Q1 FY26 (Jun 30, 2025) | $328.00K | −$1.60M | −$0.02 |
| Q2 FY26 (Sep 30, 2025) | $191.00K | −$1.82M | −$0.02 |
| Q3 FY26 (Dec 31, 2025) | $350.00K | −$726.00K | −$0.01 |
| Q4 FY26 (Mar 31, 2026) | $317.00K | −$2.40M | −$0.02 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Mar 31, 2021) | $898.00K | −$8.81M | −$0.21 |
| FY22 (Mar 31, 2022) | $397.00K | −$15.02M | −$0.30 |
| FY23 (Mar 31, 2023) | $911.00K | −$11.51M | −$0.22 |
| FY24 (Mar 31, 2024) | $1.35M | −$13.00M | −$0.22 |
| FY25 (Mar 31, 2025) | $1.27M | −$7.12M | −$0.09 |
Margins
- Gross 29.7%
- Operating −860.3%
- Net −552.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$5.31MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$5.94MLast 12 months
- Capital spending$631.00KLast 12 months
- −447.9%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $5.32MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $472.00KAs of Mar 31, 2026
Cash plus short- and long-term marketable securities on the Mar 31, 2026 balance sheet.
- Total debt$917.00KAs of Mar 31, 2026
- Net debt$445.00KAs of Mar 31, 2026
- 0.40As of Mar 31, 2026
Current assets divided by current liabilities on the Mar 31, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.15As of Mar 31, 2026
Total debt divided by shareholders’ equity on the Mar 31, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −94.5%Last 12 months
Over the last 12 months, IGC Pharma lost money: its net loss was 94.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −71.6%Last 12 months
Over the last 12 months, IGC Pharma’s net loss was 71.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About IGC Pharma Inc
IGC Pharma is pioneering innovative solutions to combat Alzheimer's disease and related challenges. The IGC Pharma portfolio comprises five assets, all with a singular mission - to transform the landscape of Alzheimer's treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently in a Phase 2b clinical trial for agitation in dementia due to Alzheimer's ( clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer's disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer's therapy. In parallel, IGC Pharma is at the forefront of Generative AI development, with projects including clinical trials, early detection of Alzheimer’s, and drug interactions with cannabinoids.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Maryland, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE American
- Asset type
- Common stock
- Price history since
IGC news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
IGC stock FAQ
What is IGC stock’s price today?
IGC Pharma (IGC) traded at $0.20 at the close on , up $0.01 (5.82%) from the previous close of $0.19. Over the past 52 weeks it has traded between $0.08 and $0.40.
If you invested $1,000 in IGC 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in IGC on would be worth about $516 at the close on , a total return of −48.4%. The same $1,000 would be worth $142 if invested five years ago, $519 if invested one year ago, and $4 if invested 20 years ago. Past performance doesn’t predict future returns.
What is IGC’s P/E ratio?
IGC’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.07).
How much revenue does IGC Pharma make?
IGC Pharma reported $1.2 million of revenue over the four quarters to , down 6.7% from the twelve months before. In its latest quarter (Q4 FY26, ended ) revenue was $317.0 thousand, down 3.9% from a year earlier.
Is IGC Pharma profitable?
Not over the four quarters to . IGC Pharma reported a net loss of $6.5 million across those four quarters on $1.2 million of revenue.
What are IGC’s earnings per share?
IGC’s diluted earnings per share were −$0.07 over the four quarters to , compared with −$0.09 in the twelve months before. The latest quarter (Q4 FY26) brought −$0.02 per share, against −$0.02 a year earlier (how EPS works).
Does IGC pay a dividend?
IGC Pharma hasn’t paid a dividend in the last twelve months.
What is IGC’s 52-week high and low?
Over the past 52 weeks IGC has traded as low as $0.08 and as high as $0.40. At $0.20 at the close on , it is 50.5% below that high and 150.0% above the low.
What is IGC’s all-time high?
IGC’s highest closing price was $59.40 on , adjusted for stock splits. At $0.20 at the close on , it is 99.7% below that record.
Has IGC stock ever split?
Yes, once: 1-for-10 on .
How has IGC stock performed?
Including dividends and measured to the close on , IGC has returned −28.9% so far this year and −48.1% over the past year, and −85.8% over five years (−32.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is IGC Pharma in?
IGC Pharma is in the Healthcare sector and the Biotechnology industry, and is headquartered in Maryland, USA.
What exchange does IGC trade on?
IGC Pharma trades on the NYSE American under the ticker symbol IGC. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.